As we previously reported, Amgen appealed the Southern District of Florida’s judgment of non-infringement in favor of Apotex in litigation regarding Apotex’s proposed filgrastim and pegfilgrastim biosimilars.  Today the Federal Circuit issued a decision affirming the district court’s finding of non-infringement.

We will post a summary of the opinion later today.